About Merus
Merus: Revolutionizing Cancer Treatment with Innovative Therapies
At Merus, we are committed to transforming the way cancer is treated. Our mission is to help patients declare victory over cancer by developing innovative therapies that target the root cause of the disease.
Founded in 2003, Merus has emerged as a leading biotechnology company that specializes in developing bispecific antibodies for cancer treatment. Our proprietary technology platform enables us to create novel therapeutics that can simultaneously bind two different targets on cancer cells, thereby enhancing their efficacy and reducing side effects.
Our team of experienced scientists and researchers work tirelessly to develop cutting-edge therapies that can address unmet medical needs in oncology. We have a deep understanding of the complex biology of cancer and leverage this knowledge to design targeted therapies that can selectively kill tumor cells while sparing healthy tissues.
One of our most promising products is Zenocutuzumab (Zeno), a bispecific antibody designed to target HER2 and HER3 receptors on tumor cells. Zeno has shown remarkable efficacy in preclinical studies and is currently being evaluated in clinical trials for various types of solid tumors, including breast, ovarian, lung, gastric, and colorectal cancers.
In addition to Zeno, we have several other bispecific antibodies in our pipeline that target different pathways involved in tumor growth and survival. These include MCLA-158 (CD3xCD158), which targets NKG2A receptor on immune cells; MCLA-145 (CD137xCD3), which activates T-cells against tumors; MCLA-117 (PD-L1xCD137), which blocks PD-L1 checkpoint inhibitor; among others.
At Merus, we believe that collaboration is key to advancing science and improving patient outcomes. That's why we partner with leading pharmaceutical companies such as Incyte Corporation, Eli Lilly & Company, Baxalta US Inc., among others. Through these collaborations, we aim to accelerate the development of our pipeline products and bring them closer to patients who need them most.
We are also committed to fostering a culture of innovation at Merus by investing heavily in research & development activities. We have state-of-the-art facilities located across Europe and North America where our scientists work tirelessly towards discovering new therapeutic targets for cancer treatment.
In conclusion,
Merus is an innovative biotechnology company dedicated towards revolutionizing cancer treatment through its proprietary technology platform for developing bispecific antibodies targeting multiple pathways involved in tumor growth & survival. With promising products like Zenocutuzumab (Zeno) already showing remarkable efficacy against various types of solid tumors during clinical trials along with several other bispecific antibodies under development targeting different pathways involved with tumour growth & survival - it's no wonder why they're quickly becoming one amongst top players within this space!
merus.nl
